MutL缺失通过CDK4/6破坏CHK2依赖性细胞周期调控从而促进原发性乳腺癌内在内分泌治疗耐药
在≥20%的雌激素受体阳性(ER+)原发性乳腺癌中存在显著的内分泌治疗耐药性肿瘤增殖,并与疾病复发和死亡相关。本研究发现MutL错配修复复合物(MLH1/3、PMS1/2)失调与内在内分泌治疗耐药相关,MutL缺失通过削弱CHK2对CDK4的抑制导致对各类内分泌治疗耐药,而CDK4/6抑制剂在MutL缺陷的ER+乳腺癌细胞中仍然有效,临床试验数据支持CDK4/6抑制剂可强烈抑制MutL缺陷肿瘤对芳香化酶抑制剂的耐药性增殖。这些数据提示MutL缺陷的诊断标志物可用于指导辅助CDK4/6抑制剂用于对当前标准治疗明显耐药的乳腺癌患者人群。
要点
- ≥20%的ER+原发性乳腺癌存在显著的内分泌治疗耐药性肿瘤增殖,与复发和死亡相关。
- MutL缺失通过削弱CHK2对CDK4的抑制导致对各类内分泌治疗耐药。
- CDK4/6抑制剂在MutL缺陷的ER+乳腺癌细胞中仍然有效,临床试验数据支持其可强烈抑制MutL缺陷肿瘤对芳香化酶抑制剂的耐药性增殖。
核心结论
- MutL缺失通过破坏CHK2依赖性CDK4抑制导致ER+乳腺癌对各类内分泌治疗耐药,CDK4/6抑制剂在MutL缺陷肿瘤中仍然有效,MutL缺陷标志物可能指导辅助CDK4/6抑制剂的使用。
研究设计与样本
- 本研究为实验研究,包括细胞水平分析和一项临床试验数据支持,具体样本量原文未报告。
主要发现
- 在≥20%的ER+原发性乳腺癌中存在显著的内分泌治疗耐药性肿瘤增殖,并与疾病复发和死亡相关。
- ER+乳腺癌中MutL缺陷削弱CHK2介导的CDK4抑制,而这是内分泌治疗应答的先决条件。
- CDK4/6抑制剂在MutL缺陷的ER+乳腺癌细胞中仍然有效。
- 临床试验数据显示CDK4/6抑制剂强烈抑制MutL缺陷肿瘤对芳香化酶抑制剂的耐药性增殖。
关键数值与推荐
- 原文未报告具体阈值或推荐等级。
临床怎么用
- 作者认为MutL缺陷的诊断标志物可用于指导辅助CDK4/6抑制剂用于对当前标准治疗明显耐药的乳腺癌患者人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significant endocrine therapy-resistant tumor proliferation is present in ≥20% of estrogen receptor-positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismatch repair (MMR) complex (MLH1/3, PMS1/2), and demonstrate a direct role for MutL complex loss in resistance to all classes of endocrine therapy. We find that MutL deficiency in ER+ breast cancer abrogates CHK2-mediated inhibition of CDK4, a prerequisite for endocrine therapy responsiveness. Consequently, CDK4/6 inhibitors (CDK4/6i) remain effective in MutL-defective ER+ breast cancer cells. These observations are supported by data from a clinical trial where a CDK4/6i was found to strongly inhibit aromatase inhibitor-resistant proliferation of MutL-defective tumors. These data suggest that diagnostic markers of MutL deficiency could be used to direct adjuvant CDK4/6i to a population of patients with breast cancer who exhibit marked resistance to the current standard of care.Significance: MutL deficiency in a subset of ER+ primary tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy-resistant tumors. Therefore, markers of MutL dysregulation could guide CDK4/6 inhibitor use in the adjuvant setting, where the risk benefit ratio for untargeted therapeutic intervention is narrow. Cancer Discov; 7(10); 1168-83. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047.
引用
- Haricharan S, Punturi N, Singh P, et al. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017. PMID: 28801307. doi:10.1158/2159-8290.CD-16-1179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。